California Pacific Medical Center
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 050047
- Received
- $1,844,215 in 230 records, 2020 ($59,019 general, $1,785,196 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 8 | $59,019 |
| 2020 | Research payment | 222 | $1,785,196 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Gilead Sciences, Inc. | 39 | $851,431 | 2020 |
| Merck Sharp & Dohme LLC | 50 | $400,154 | 2020 |
| Genentech, Inc. | 60 | $264,787 | 2020 |
| Intercept Pharmaceuticals, Inc. | 9 | $53,267 | 2020 |
| Amgen Inc. | 10 | $42,942 | 2020 |
| Jenavalve Technology, Inc. | 1 | $41,465 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $35,539 | 2020 |
| Novocure Inc. | 3 | $29,811 | 2020 |
| ARRAY BIOPHARMA INC | 6 | $16,734 | 2020 |
| Orion Corporation | 3 | $15,492 | 2020 |
| Stryker Corporation | 4 | $14,400 | 2020 |
| Medtronic Vascular, Inc. | 3 | $13,800 | 2020 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | 1 | $11,800 | 2020 |
| PFIZER INC. | 6 | $8,861 | 2020 |
| Astellas Pharma Global Development | 2 | $6,211 | 2020 |
| Eli Lilly and Company | 1 | $5,674 | 2020 |
| Mallinckrodt Hospital Products Inc. | 1 | $5,050 | 2020 |
| Gyrus ACMI, Inc. | 2 | $5,000 | 2020 |
| F. Hoffmann-La Roche AG | 3 | $5,000 | 2020 |
| Vanda Pharmaceuticals Inc. | 3 | $4,673 | 2020 |
| Aesculap, Inc. | 3 | $3,154 | 2020 |
| Roche Products Limited | 1 | $2,961 | 2020 |
| Penumbra, Inc. | 2 | $1,850 | 2020 |
| VIVUS LLC | 3 | $1,243 | 2020 |
| Allergan, Inc. | 1 | $1,231 | 2020 |
| Spiration, Inc. | 1 | $992 | 2020 |
| CSL Behring | 1 | $687 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 222 | $1,785,196 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $41,465 |
| Space rental or facility fees (teaching hospital only) | 4 | $14,400 |
| Gift | 3 | $3,154 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-30 | Merck Sharp & Dohme LLC | $4,838 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $22,562 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $8,979 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $11,013 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | $2,139 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-12-21 | Genentech, Inc. | $572 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-12-18 | Medtronic Vascular, Inc. | $650 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2020 |
| 2020-12-18 | Genentech, Inc. | $572 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $773 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-12-17 | Intercept Pharmaceuticals, Inc. | $185 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-17 | Intercept Pharmaceuticals, Inc. | $179 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $1,550 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | Genentech, Inc. | $130 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERJETA SAFETY STUDY IN NEO ADJUVANT BC | 2020 |
| 2020-12-14 | Genentech, Inc. | $3,300 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-12-14 | Genentech, Inc. | $1,428 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-12-11 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Drug | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-12-11 | ARRAY BIOPHARMA INC | $650 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-10 | Aesculap, Inc. | $1,730 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $824 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $600 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Merck Sharp & Dohme LLC | $19,739 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2020 |
| 2020-12-09 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2020 |
| 2020-12-04 | Genentech, Inc. | $7,040 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-12-03 | Stryker Corporation | $3,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-03 | Stryker Corporation | $3,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-03 | Stryker Corporation | $3,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-03 | Stryker Corporation | $3,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-03 | Genentech, Inc. | $1,223 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $1,200 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $36,576 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2020 |
| 2020-12-01 | Genentech, Inc. | $5,615 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-12-01 | Genentech, Inc. | $1,235 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-11-30 | Vanda Pharmaceuticals Inc. | $2,530 | Research payment | Cash or cash equivalent | STUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS | 2020 | |
| 2020-11-24 | Genentech, Inc. | $2,970 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-11-20 | Genentech, Inc. | $4,398 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2020 |
| 2020-11-19 | Merck Sharp & Dohme LLC | $519 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $5,189 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-11-18 | Medtronic Vascular, Inc. | $650 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2020 |
| 2020-11-17 | Merck Sharp & Dohme LLC | $16,641 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-11-17 | Genentech, Inc. | $1,325 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-11-16 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-11-16 | F. Hoffmann-La Roche AG | $500 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2020 |
| 2020-11-05 | Genentech, Inc. | $1,532 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-11-04 | Genentech, Inc. | $48,211 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-10-28 | Gyrus ACMI, Inc. | $4,500 | Research payment | Cash or cash equivalent | SVS Device, EndoTherapy | Valves Against Standard Therapy | 2020 |
| 2020-10-28 | Gyrus ACMI, Inc. | $500 | Research payment | Cash or cash equivalent | SVS Device, EndoTherapy | Valves Against Standard Therapy | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $9,910 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $115 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-10-26 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-10-26 | Genentech, Inc. | $1,627 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-10-22 | Genentech, Inc. | $4,697 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-10-22 | PFIZER INC. | $2,350 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $3,757 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-10-19 | Novocure Inc. | $27,650 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2020 |
| 2020-10-19 | Genentech, Inc. | $1,550 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-10-13 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-10-08 | Penumbra, Inc. | $1,725 | Research payment | Cash or cash equivalent | 3D Revascularization Device, Neurointervention | COMPLETE | 2020 |
| 2020-10-06 | Takeda Pharmaceuticals U.S.A., Inc. | $280 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-10-05 | Orion Corporation | $8,480 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2020 | |
| 2020-10-05 | Orion Corporation | $5,250 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2020 | |
| 2020-10-01 | Genentech, Inc. | $18,008 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2020 |
| 2020-10-01 | Genentech, Inc. | $769 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2020 |
| 2020-09-29 | Merck Sharp & Dohme LLC | $3,045 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $18,932 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $27 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-09-18 | Genentech, Inc. | $4,600 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-09-17 | Vanda Pharmaceuticals Inc. | $583 | Research payment | Cash or cash equivalent | STUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS | 2020 | |
| 2020-09-17 | Merck Sharp & Dohme LLC | $537 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2020 |
| 2020-09-16 | Genentech, Inc. | $10,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2020 |
| 2020-09-16 | Novocure Inc. | $1,589 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2020 |
| 2020-09-16 | Novocure Inc. | $572 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2020 |
| 2020-09-16 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2020 |
| 2020-09-16 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2020 |
| 2020-09-14 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $5,900 | Research payment | Cash or cash equivalent | A STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI | 2020 | |
| 2020-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $4,271 | Research payment | Cash or cash equivalent | A STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI | 2020 | |
| 2020-09-11 | Genentech, Inc. | $1,653 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERJETA SAFETY STUDY IN NEO ADJUVANT BC | 2020 |
| 2020-09-10 | Genentech, Inc. | $2,200 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-09-03 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $11,800 | Research payment | Cash or cash equivalent | SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS | 2020 | |
| 2020-09-03 | Intercept Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-08-27 | Genentech, Inc. | $12,615 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-08-27 | Genentech, Inc. | $425 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERJETA SAFETY STUDY IN NEO ADJUVANT BC | 2020 |
| 2020-08-26 | Merck Sharp & Dohme LLC | $77 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-25 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-08-25 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2020 |
| 2020-08-21 | Genentech, Inc. | $4,355 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-20 | Merck Sharp & Dohme LLC | $3,788 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-19 | Medtronic Vascular, Inc. | $12,500 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | Optimize Pro | 2020 |
| 2020-08-18 | Genentech, Inc. | $5,959 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $4,866 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,804 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,804 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,530 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,530 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,530 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,530 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,530 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Genentech, Inc. | $1,027 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-08-18 | Merck Sharp & Dohme LLC | $400 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-12 | Gilead Sciences, Inc. | $10,303 | Research payment | Cash or cash equivalent | STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonserti | 2020 | |
| 2020-08-06 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-08-06 | VIVUS LLC | $298 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-08-04 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-07-30 | Merck Sharp & Dohme LLC | $800 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-28 | Genentech, Inc. | $3,750 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-07-28 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $9,527 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $4,100 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $2,235 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $1,788 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $1,341 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $447 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $447 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,946 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-07-16 | VIVUS LLC | $750 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-07-06 | F. Hoffmann-La Roche AG | $3,500 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC | 2020 |
| 2020-07-03 | Genentech, Inc. | $18,407 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-07-02 | Genentech, Inc. | $819 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-06-26 | ARRAY BIOPHARMA INC | $1,300 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-06-25 | Genentech, Inc. | $9,384 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-06-25 | Merck Sharp & Dohme LLC | $805 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-06-22 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-06-22 | Merck Sharp & Dohme LLC | $8,314 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-06-19 | Genentech, Inc. | $1,550 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-06-18 | Intercept Pharmaceuticals, Inc. | $8,260 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $125,708 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $125,258 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $85,187 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $55,218 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $44,563 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $38,415 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $38,030 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $1,879 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-09 | Merck Sharp & Dohme LLC | $4,083 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-06-03 | Gilead Sciences, Inc. | $8,800 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-06-01 | Genentech, Inc. | $7,957 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $4,119 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $3,500 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $750 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $550 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-05-28 | Genentech, Inc. | $3,750 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-05-28 | Intercept Pharmaceuticals, Inc. | $3,152 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-05-28 | Merck Sharp & Dohme LLC | $1,944 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $57,801 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $46,218 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $27,015 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $17,547 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $10,131 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $8,079 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $1,879 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-19 | Genentech, Inc. | $11,877 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-05-13 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-13 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-11 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-05-05 | Amgen Inc. | $4,860 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | 2020 |
| 2020-05-01 | Genentech, Inc. | $572 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2020 |
| 2020-04-27 | Merck Sharp & Dohme LLC | $51 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-04-20 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-04-20 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-04-16 | Merck Sharp & Dohme LLC | $4,583 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-04-16 | Intercept Pharmaceuticals, Inc. | $2,250 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-04-09 | Jenavalve Technology, Inc. | $41,465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | JenaValve Pericardial TAVR System Device, Cardiology | 2020 | |
| 2020-04-09 | Genentech, Inc. | $11,096 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | PHASE III BRAF MEK COMBINATION | 2020 |
| 2020-04-06 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-04-06 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-04-01 | Genentech, Inc. | $7,018 | Research payment | Cash or cash equivalent | Drug | PH 1A SAD OF GDC 0134 IN ALS PATIENTS | 2020 |
| 2020-03-31 | Spiration, Inc. | $992 | Research payment | Cash or cash equivalent | Spiration Valve System Device, EndoTherapy Products | A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val | 2020 |
| 2020-03-30 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-03-30 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-03-30 | Gilead Sciences, Inc. | $10,201 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-03-30 | Genentech, Inc. | $2,021 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2020 |
| 2020-03-30 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2020 |
| 2020-03-26 | Merck Sharp & Dohme LLC | $5,426 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2020 |
| 2020-03-26 | Merck Sharp & Dohme LLC | $696 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu | 2020 |
| 2020-03-26 | CSL Behring | $687 | Research payment | In-kind items and services | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-03-24 | Genentech, Inc. | $1,589 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-03-24 | Astellas Pharma Global Development | $1,000 | Research payment | Cash or cash equivalent | ASTAGRAF XL Drug, IMMUNOLOGY | ASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KI | 2020 |
| 2020-03-23 | Takeda Pharmaceuticals U.S.A., Inc. | $8,469 | Research payment | Cash or cash equivalent | A STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI | 2020 | |
| 2020-03-21 | Amgen Inc. | $4,977 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2020 | |
| 2020-03-20 | Amgen Inc. | $5,449 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P2 Neo-adjuvant melanoma | 2020 |
| 2020-03-20 | Genentech, Inc. | $990 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GDC0068 COMB W TAXOTERE OR FOLFOX | 2020 |
| 2020-03-18 | Gilead Sciences, Inc. | $9,553 | Research payment | Cash or cash equivalent | STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonserti | 2020 | |
| 2020-03-16 | Merck Sharp & Dohme LLC | $1,590 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2020 |
| 2020-03-09 | Roche Products Limited | $2,961 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | PHASE II STUDY IN RRMS | 2020 |
| 2020-03-02 | Genentech, Inc. | $870 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER | 2020 |
| 2020-02-28 | PFIZER INC. | $3,310 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE | 2020 |
| 2020-02-21 | Astellas Pharma Global Development | $5,211 | Research payment | Cash or cash equivalent | ASTAGRAF XL Drug, IMMUNOLOGY | ASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KI | 2020 |
| 2020-02-20 | Intercept Pharmaceuticals, Inc. | $8,610 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-02-20 | Intercept Pharmaceuticals, Inc. | $7,315 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-02-20 | PFIZER INC. | $2,161 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2020 |
| 2020-02-20 | PFIZER INC. | $540 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2020 |
| 2020-02-20 | PFIZER INC. | $250 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2020 |
The latest 200 records of 230.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments